Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
A
Anna Neyman
Primary Investigator
Enrolling By Invitation
7-18 years
All
Phase
N/A
1 participants needed
3 Locations
Overview
The aim of this study is to learn more about the long-term effectiveness of hybrid closed-loop system and verapamil in treating type 1 diabetes.
Description
Participants who have participated in the first CLVer trial are eligible to join the extended CLVer trial. Researchers will contact participants every three months and ask about continuous glucose monitoring data and health history. Researchers will invite participants to a yearly in-person visit. Participants will be enrolled in this study for three years.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Type 1 diabetes
-
Age: Between 7 Years - 18 Years
-
Gender: All
Inclusion Criteria:
- Has participated in the previous CLVer trial
- Able and willing to provide informed consent
Exclusion Criteria:
- Unable or unwilling to provide informed consent
Updated on
01 Aug 2024.
Study ID: 12034, PENDO-IIR-CLVER-EXT
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
